{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:36:47Z","timestamp":1793147807413,"version":"4.5.0"},"reference-count":72,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: SARS-CoV-2 vaccination is crucial for protecting against severe COVID-19 disease; however, patients with haematological malignancies (HM) respond poorly to vaccination due to immunosuppression driven by chemotherapy, targeted cell depletion, and immune dysregulation. We sought to define novel biomarkers that predict effective vaccination in patients with HM. Methods: HM patients and healthy controls received SARS-CoV-2 vaccines and were followed for six months post-vaccination. Virus-specific humoral and cellular immune responses were analysed in serum and whole blood pre- and post-vaccination, and serum proteomics was analysed pre-vaccination to identify potential biomarkers for vaccine response. Results: HM patients displayed delayed antibody seroconversion, and 37.5% failed to seroconvert. Baseline proteomic and cellular immune profiles revealed that T-cell-associated chemokines CXCL13 and CRTAM were differentially expressed, with decreased levels seen in vaccine non-responders. Vaccine response was also associated with a reduced frequency of circulating monocytes, greater numbers of B-cells, and a trend toward greater numbers of CD4+ helper cell phenotypes, including T peripheral helper cells pre-vaccination. In vitro generation of COVID-19-specific T-cells from a subset of participants trended towards increased cytotoxic CD4+ and CD8+ T-cell activity in seroconverters and dysfunctional COVID-19-specific T-cell responses in non-seroconverters. Conclusions: These results suggest that HM patients have impaired T-cell immunity, and non-responders may be identified by low levels of serum CXCL13 and CRTAM. This allows for the identification of at-risk patients who would benefit from alternative COVID-19 prophylaxis strategies.<\/jats:p>","DOI":"10.3390\/vaccines14030201","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T09:31:32Z","timestamp":1772098292000},"page":"201","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prospective Biomarkers of SARS-CoV-2 Vaccine Seroconversion in Patients with Haematological Malignancies"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8371-2473","authenticated-orcid":false,"given":"Sophie C.","family":"Hamann","sequence":"first","affiliation":[{"name":"Queensland Institute of Medical Research Berghofer, Herston, QLD 4006, Australia"},{"name":"Queensland Immunology Research Centre, Brisbane, QLD 4000, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5712-2610","authenticated-orcid":false,"given":"Katie E.","family":"Lineburg","sequence":"additional","affiliation":[{"name":"Queensland Institute of Medical Research Berghofer, Herston, QLD 4006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Ng","sequence":"additional","affiliation":[{"name":"Queensland Institute of Medical Research Berghofer, Herston, QLD 4006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6758-7502","authenticated-orcid":false,"given":"Annabel","family":"Waugh","sequence":"additional","affiliation":[{"name":"Queensland Institute of Medical Research Berghofer, Herston, QLD 4006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Olver","sequence":"additional","affiliation":[{"name":"Queensland Institute of Medical Research Berghofer, Herston, QLD 4006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Leach","sequence":"additional","affiliation":[{"name":"Cancer Care Services, Royal Brisbane and Women\u2019s Hospital, Herston, QLD 4006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Bristow","sequence":"additional","affiliation":[{"name":"Cancer Care Services, Royal Brisbane and Women\u2019s Hospital, Herston, QLD 4006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyothy","family":"Raju","sequence":"additional","affiliation":[{"name":"Queensland Institute of Medical Research Berghofer, Herston, QLD 4006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia Le","family":"Texier","sequence":"additional","affiliation":[{"name":"Queensland Institute of Medical Research Berghofer, Herston, QLD 4006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Crooks","sequence":"additional","affiliation":[{"name":"Queensland Institute of Medical Research Berghofer, Herston, QLD 4006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Smith","sequence":"additional","affiliation":[{"name":"Queensland Institute of Medical Research Berghofer, Herston, QLD 4006, Australia"},{"name":"Queensland Immunology Research Centre, Brisbane, QLD 4000, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristyan","family":"Guppy-Coles","sequence":"additional","affiliation":[{"name":"Cancer Care Services, Royal Brisbane and Women\u2019s Hospital, Herston, QLD 4006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk","family":"Morris","sequence":"additional","affiliation":[{"name":"Cancer Care Services, Royal Brisbane and Women\u2019s Hospital, Herston, QLD 4006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1498-7822","authenticated-orcid":false,"given":"Michelle","family":"Spanevello","sequence":"additional","affiliation":[{"name":"Cancer Care Services, Royal Brisbane and Women\u2019s Hospital, Herston, QLD 4006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siok-Keen","family":"Tey","sequence":"additional","affiliation":[{"name":"Queensland Institute of Medical Research Berghofer, Herston, QLD 4006, Australia"},{"name":"Cancer Care Services, Royal Brisbane and Women\u2019s Hospital, Herston, QLD 4006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2261-169X","authenticated-orcid":false,"given":"Andrea S.","family":"Henden","sequence":"additional","affiliation":[{"name":"Queensland Institute of Medical Research Berghofer, Herston, QLD 4006, Australia"},{"name":"Cancer Care Services, Royal Brisbane and Women\u2019s Hospital, Herston, QLD 4006, Australia"},{"name":"Faculty of Health, Medicine and Behavioural Sciences, University of Queensland, St Lucia, QLD 4067, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2025, August 12). WHO COVID-19 Dashboard. Available online: https:\/\/data.who.int\/dashboards\/covid19\/deaths?n=o."},{"key":"ref_2","unstructured":"U.S. Centers for Disease Control and Prevention (CDC) (2025, August 12). Symptoms of COVID-19, Available online: https:\/\/www.cdc.gov\/covid\/signs-symptoms\/index.html."},{"key":"ref_3","first-page":"e86534","article-title":"Factors Associated With Mortality in Leukemia and Lymphoma With COVID-19: A National Inpatient Sample Analysis (2020\u20132021)","volume":"17","author":"Shekar","year":"2025","journal-title":"Cureus"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.cell.2020.10.049","article-title":"Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer","volume":"183","author":"Avanzato","year":"2020","journal-title":"Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S2352-3026(20)30429-4","article-title":"Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: An observational cohort study","volume":"8","author":"Sharma","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_6","first-page":"713","article-title":"COVID-19 after hematopoietic stem cell transplantation: Report of two children","volume":"56","author":"Fernandes","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1158\/2159-8290.CD-21-1033","article-title":"Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies","volume":"12","author":"Lee","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41586-021-03291-y","article-title":"SARS-CoV-2 evolution during treatment of chronic infection","volume":"592","author":"Kemp","year":"2021","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41586-021-03647-4","article-title":"SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans","volume":"595","author":"Turner","year":"2021","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41586-023-06025-4","article-title":"SARS-CoV-2 Omicron boosting induces de novo B cell response in humans","volume":"617","author":"Alsoussi","year":"2023","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41586-022-04527-1","article-title":"Germinal centre-driven maturation of B cell response to mRNA vaccination","volume":"604","author":"Kim","year":"2022","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/s41591-021-01386-7","article-title":"CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer","volume":"27","author":"Bange","year":"2021","journal-title":"Nat. Med."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Tiselius, E., Sundberg, E., Ramilo Amor, A., Andersson, H., Varnaite, R., Kolstad, L., Akaberi, D., Ling, J., Harila, A., and Saghafian-Hedengren, S. (2025). The quantity and quality of B-cell immunity against SARS-CoV-2 in children with cancer and hematological diseases. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1613778"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"101399","DOI":"10.1016\/j.beha.2022.101399","article-title":"COVID-19 and HSCT (Hematopoietic stem cell transplant)","volume":"35","author":"Strasfeld","year":"2022","journal-title":"Best Pr. Res. Clin. Haematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0140-6736(21)01744-X","article-title":"Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): A randomised, controlled, open-label, adaptive platform trial","volume":"398","author":"Yu","year":"2021","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e13625","DOI":"10.1111\/tid.13625","article-title":"Clinical presentation and outcomes of COVID-19 following hematopoietic cell transplantation and cellular therapy","volume":"23","author":"Camargo","year":"2021","journal-title":"Transpl. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/s41375-025-02649-9","article-title":"Post-pandemic recommendations for the management of COVID-19 in patients with haematological malignancies or undergoing cellular therapy, from the European Conference on Infections in Leukaemia (ECIL-10)","volume":"39","author":"Cesaro","year":"2025","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e70038","DOI":"10.1002\/cti2.70038","article-title":"Allogeneic \u2018off-the-shelf\u2019 SARS-CoV-2-specific adoptive T-cell therapy for refractory viral infection and end organ disease","volume":"14","author":"Henden","year":"2025","journal-title":"Clin. Transl. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1093\/cid\/ciaf302","article-title":"Effectiveness and Safety of Autologous Virus-Specific T-Cell Therapy for Persistent COVID-19 in People With Immunocompromise: A Clinical Trial Study","volume":"81","author":"Lee","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s11357-023-00858-7","article-title":"Effective virus-specific T-cell therapy for high-risk SARS-CoV-2 infections in hematopoietic stem cell transplant recipients: Initial case studies and literature review","volume":"46","author":"Gopcsa","year":"2023","journal-title":"GeroScience"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/s41375-022-01578-1","article-title":"Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)","volume":"36","author":"Cesaro","year":"2022","journal-title":"Leukemia"},{"key":"ref_22","unstructured":"Australian Technical Advisory Group on Immunisation (2022). Australian Immunisation Handbook."},{"key":"ref_23","first-page":"10","article-title":"Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology","volume":"29","author":"Khawaja","year":"2022","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"127473","DOI":"10.1016\/j.vaccine.2025.127473","article-title":"SARS-CoV-2 vaccine failure rates and predictors of immune response in a diverse immunocompromised patient population","volume":"62","author":"Greenberg","year":"2025","journal-title":"Vaccine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.clml.2024.01.004","article-title":"Serologic Response to Vaccine for COVID-19 in Patients with Hematologic Malignancy: A Prospective Cohort Study","volume":"24","author":"Hillyer","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5691","DOI":"10.1182\/bloodadvances.2022008827","article-title":"Outcomes of breakthrough COVID-19 infections in patients with hematologic malignancies","volume":"7","author":"Chien","year":"2023","journal-title":"Blood Adv."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e920","DOI":"10.1093\/cid\/ciab930","article-title":"Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Immunogenicity and Reactogenicity","volume":"75","author":"Sherman","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/bjh.18312","article-title":"Impaired humoral and cellular response to primary COVID-19 vaccination in patients less than 2 years after allogeneic bone marrow transplant","volume":"198","author":"Murray","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1182\/bloodadvances.2021006937","article-title":"Deficiency of SARS-CoV-2 T-cell responses after vaccination in long-term allo-HSCT survivors translates into abated humoral immunity","volume":"6","author":"Einarsdottir","year":"2022","journal-title":"Blood Adv."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Sava\u015f, E.M., Y\u0131ld\u0131z, \u015e., \u00d6zkurt, Z.N., Baltac\u0131, Z., Tun\u00e7can, \u00d6.G., Ye\u011fin, Z.A., \u00c7a\u011flar, K., K\u00f6kt\u00fcrk, N., Erba\u015f, G., and Bozday\u0131, G. (2025). COVID-19 Vaccine Response in Allo-HSCT Recipients: Insights from a Real-World Prospective Cohort Study. Vaccines, 13.","DOI":"10.3390\/vaccines13070726"},{"key":"ref_31","first-page":"30","article-title":"SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group","volume":"97","author":"Martino","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e1219","DOI":"10.1002\/cti2.1219","article-title":"Rapid detection of SARS-CoV-2-specific memory T-cell immunity in recovered COVID-19 cases","volume":"9","author":"Lineburg","year":"2020","journal-title":"Clin. Transl. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e1326","DOI":"10.1002\/cti2.1326","article-title":"Rapid whole-blood assay to detect SARS-CoV-2-specific memory T-cell immunity following a single dose of AstraZeneca ChAdOx1-S COVID-19 vaccine","volume":"10","author":"Lineburg","year":"2021","journal-title":"Clin. Transl. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"113044","DOI":"10.1016\/j.isci.2025.113044","article-title":"T cell epitope mapping reveals immunodominance of evolutionarily conserved regions within SARS-CoV-2 proteome","volume":"28","author":"Brown","year":"2025","journal-title":"iScience"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e789","DOI":"10.1016\/S2665-9913(21)00251-4","article-title":"Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): An investigator-initiated, single-centre, open-label study","volume":"3","author":"Moor","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41541-025-01284-w","article-title":"Associations between genetic variations of HLA and IGHV, vaccination schedule, and COVID-19 vaccine immunogenicity","volume":"10","author":"Ke","year":"2025","journal-title":"npj Vaccines"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41591-022-02078-6","article-title":"Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection","volume":"29","author":"Mentzer","year":"2022","journal-title":"Nat. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1182\/blood.2021013768","article-title":"Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting","volume":"139","author":"Mittelman","year":"2022","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e541","DOI":"10.1212\/WNL.0000000000013108","article-title":"Humoral- and T-Cell\u2013Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies","volume":"98","author":"Tortorella","year":"2022","journal-title":"Neurology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/bjh.18962","article-title":"Humoral and cellular responses to SARS-CoV-2 in patients with B-cell haematological malignancies improve with successive vaccination","volume":"202","author":"Pinder","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S383","DOI":"10.18103\/mra.v10i7.2932","article-title":"The Effects of an mRNA Covid-19 Vaccine Booster on Immune Responses in Cancer-Bearing Veterans","volume":"10","author":"Frankel","year":"2022","journal-title":"Med. Res. Arch."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"126547","DOI":"10.1016\/j.vaccine.2024.126547","article-title":"Comprehensive humoral and cellular immune responses to COVID-19 vaccination in adults with cancer","volume":"46","author":"Body","year":"2024","journal-title":"Vaccine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.ccell.2021.06.002","article-title":"Seroconversion rates following COVID-19 vaccination among patients with cancer","volume":"39","author":"Thakkar","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/ajco.13959","article-title":"Comparison of antibody response to coronavirus disease 2019 vaccination between patients with solid or hematologic cancer patients undergoing chemotherapy","volume":"20","author":"Lim","year":"2023","journal-title":"Asia-Pac. J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1038\/s41467-024-45549-9","article-title":"Comparing frequency of booster vaccination to prevent severe COVID-19 by risk group in the United States","volume":"15","author":"Park","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"E84","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months","volume":"385","author":"Levin","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41408-022-00684-8","article-title":"Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: A systematic review","volume":"12","author":"Piechotta","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"109046","DOI":"10.1016\/j.intimp.2022.109046","article-title":"A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies","volume":"110","author":"Noori","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"108474","DOI":"10.1016\/j.isci.2023.108474","article-title":"Breakthrough SARS-COV-2 infection induces broad anti-viral T cell immunity","volume":"26","author":"Lineburg","year":"2023","journal-title":"iScience"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"103218","DOI":"10.1016\/j.jaut.2024.103218","article-title":"Peripheral helper T cells in human diseases","volume":"145","author":"Zou","year":"2024","journal-title":"J. Autoimmun."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1073\/pnas.1520112113","article-title":"CXCL13 is a plasma biomarker of germinal center activity","volume":"113","author":"Lindqvist","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1084\/jem.20181216","article-title":"Type I interferon induces CXCL13 to support ectopic germinal center formation","volume":"216","author":"Denton","year":"2019","journal-title":"J. Exp. Med."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Mabuka, J.M., Dugast, A.-S., Muema, D.M., Reddy, T., Ramlakhan, Y., Euler, Z., Ismail, N., Moodley, A., Dong, K.L., and Morris, L. (2017). Plasma CXCL13 but Not B Cell Frequencies in Acute HIV Infection Predicts Emergence of Cross-Neutralizing Antibodies. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.01104"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e2406434121","DOI":"10.1073\/pnas.2406434121","article-title":"CXCL13 promotes broad immune responses induced by circular RNA vaccines","volume":"121","author":"Wan","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.molimm.2015.03.253","article-title":"CRTAM is negatively regulated by ZEB1 in T cells","volume":"66","year":"2015","journal-title":"Mol. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1084\/jem.20150519","article-title":"CRTAM determines the CD4+ cytotoxic T lymphocyte lineage","volume":"213","author":"Takeuchi","year":"2016","journal-title":"J. Exp. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.4049\/jimmunol.0901248","article-title":"CRTAM Confers Late-Stage Activation of CD8+ T Cells to Regulate Retention within Lymph Node","volume":"183","author":"Takeuchi","year":"2009","journal-title":"J. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"21955","DOI":"10.1074\/jbc.M502095200","article-title":"Nectin-like Protein 2 Defines a Subset of T-cell Zone Dendritic Cells and Is a Ligand for Class-I-restricted T-cell-associated Molecule","volume":"280","author":"Galibert","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1182\/blood-2005-02-0817","article-title":"The tumor suppressor TSLC1\/NECL-2 triggers NK-cell and CD8+ T-cell responses through the cell-surface receptor CRTAM","volume":"106","author":"Boles","year":"2005","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.cell.2008.01.013","article-title":"Regulation of a Late Phase of T Cell Polarity and Effector Functions by Crtam","volume":"132","author":"Yeh","year":"2008","journal-title":"Cell"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/s41467-019-08801-1","article-title":"Adenosine deaminase-1 delineates human follicular helper T cell function and is altered with HIV","volume":"10","author":"Tardif","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1189\/jlb.1009696","article-title":"Adenosine deaminase potentiates the generation of effector, memory, and regulatory CD4+ T cells","volume":"89","author":"Casanova","year":"2010","journal-title":"J. Leukoc. Biol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1084\/jem.20030916","article-title":"CD27 Promotes Survival of Activated T Cells and Complements CD28 in Generation and Establishment of the Effector T Cell Pool","volume":"198","author":"Hendriks","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood.2020009482","article-title":"CD27 is required for protective lytic EBV antigen\u2013specific CD8+ T-cell expansion","volume":"137","author":"Deng","year":"2021","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"eabg2752","DOI":"10.1126\/science.abg2752","article-title":"CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses","volume":"379","author":"He","year":"2023","journal-title":"Science"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Shimizu, K., Yamasaki, S., Sakurai, M., Yumoto, N., Ikeda, M., Mishima-Tsumagari, C., Kukimoto-Niino, M., Watanabe, T., Kawamura, M., and Shirouzu, M. (2019). Granzyme A Stimulates pDCs to Promote Adaptive Immunity via Induction of Type I IFN. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01450"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s00262-025-04120-1","article-title":"Preclinical evaluation of a CCL19 immune-potentiated DNA cancer vaccine","volume":"74","author":"Kofoed","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"143170","DOI":"10.1016\/j.ijbiomac.2025.143170","article-title":"Host genetic variation governs PCV2 susceptibility through CXCL13 and ELK1-mediated immune regulation","volume":"310","author":"Liu","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.cell.2020.10.001","article-title":"Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4+ T Cells in COVID-19","volume":"183","author":"Meckiff","year":"2020","journal-title":"Cell"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"eadj8526","DOI":"10.1126\/sciimmunol.adj8526","article-title":"SARS-CoV-2 inflammation durably imprints memory CD4 T cells","volume":"9","author":"Solis","year":"2024","journal-title":"Sci. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"20376","DOI":"10.1038\/s41598-022-24938-4","article-title":"Early CD4+ T cell responses induced by the BNT162b2 SARS-CoV-2 mRNA vaccine predict immunological memory","volume":"12","author":"Bai","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_72","unstructured":"United Nations (2025, December 02). WHO Chief Declares End to COVID-19 as a Global Health Emergency. Available online: https:\/\/news.un.org\/en\/story\/2023\/05\/1136367."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/3\/201\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T05:11:06Z","timestamp":1772255466000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/3\/201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":72,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["vaccines14030201"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14030201","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]}}}